IP Library › Granted Patent US 12,612,665
Granted Patent B2
US 12,612,665 · App. 17/757,289 · Granted Apr 28, 2026

Long non-coding RNA LETN serving as tumor marker and therapeutic target point

Inventors: Xuerui Yang (Beijing, CN); Xianteng Wang (Beijing, CN); Xiaolin Hu (Beijing, CN)
Assignee: Tsinghua University
C12Q1/6886G01N33/5011C12Q2600/136C12Q2600/158C12Q2600/178
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,612,665
App. No.
17/757,289
Granted
Apr 28, 2026
Kind
B2
Abstract

The invention relates to a long non-coding RNA (LETN) useful as a diagnostic and therapeutic target for cancer. In particular, the invention discloses that lncRNA RP11-196G18.22 (LETN) is overexpressed in cancer cells, and such overexpression can promote the proliferation of cancer cells and are associated with short prognostic survival time in cancer patients. Reducing the expression of this lncRNA results in the inhibition of cancer cell growth, and thus inhibiting the expression of this lncRNA represents a new strategy for cancer therapy.

Claims (5)

1 . A method for treating cancer, the method comprising administrating to a subject in need thereof an effective amount of an agent for reducing or inhibiting the expression of lncRNA RP11-196G18.22 (LETN),

wherein the cancer is a solid tumor selected from the group consisting of liver hepatocellular carcinoma, lung cancer, and prostate cancer.

2 . The method according to claim 1 , wherein the agent for reducing or inhibiting the expression of lncRNA RP11-196G18.22 (LETN) is selected from the group consisting of gapmer, antisense RNA, siRNA, esiRNA, shRNA, miRNA, RNA aptamer, transcription activator-like effector nuclease, CRISPR, and zinc finger nuclease.

3 . The method according to claim 1 , wherein the lncRNA RP11-196G18.22 has the nucleotide sequence as shown in SEQ ID NO: 1 (Ensembl accession number: ENST00000564237.1).

4 . The method according to claim 1 , wherein the method further comprises administrating to the subject an additional anticancer agent, wherein the additional anticancer agent comprises a chemotherapeutic agent.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2023
From: YANG, XUERUI; WANG, XIANTENG; HU, XIAOLIN
To: TSINGHUA UNIVERSITY
Reel/Frame 065827/0001 →
Continuity (1)
Related Publication 20230129013A1 · Apr 27, 2023
References Cited (47)
US 10233495B2 · Hatchwell · 2019 [cited by applicant]
US 11591601B2 · Joung · 2023 [cited by applicant]
US 11667974B2 · Firat · 2023 [cited by applicant]
US 20130178428A1 · Hoon · 2013 [cited by applicant]
US 20150329858A1 · Aburatani · 2015 [cited by applicant]
US 20200248184A1 · Joung · 2020 [cited by applicant]
US 20210189491A1 · Firat · 2021 [cited by applicant]
CN 104726570A · 2015 [cited by applicant]
CN 105274111A · 2016 [cited by applicant]
CN 105316402A · 2016 [cited by applicant]
CN 105950628A · 2016 [cited by applicant]
CN 106434868A · 2017 [cited by applicant]
CN 107022625A · 2017 [cited by applicant]
CN 107213161A · 2017 [cited by applicant]
CN 107236817A · 2017 [cited by applicant]
CN 108384855A · 2018 [cited by applicant]
CN 108531596A · 2018 [cited by applicant]
CN 109593848A · 2019 [cited by applicant]
CN 109722479A · 2019 [cited by applicant]
JP 2016529246A · 2016 [cited by applicant]
WO WO2018204777A2 · 2018 [cited by applicant]
WO WO2018229046A1 · 2018 [cited by applicant]
WO WO2018219264A1 · 2018 [cited by applicant]
WO WO2019095541A1 · 2019 [cited by applicant]
Zhang et al., Systematic identification of cancer-related long noncoding RNAs and aberrant alternative splicing of quintuple-negative lung adenocarcinoma through RNA-Seq. Lung Cancer (2017), 109: 21-27 (Year: 2017). [cited by examiner]
Jiang et al., Emerging roles of IncRNA in cancer and therapeutic opportunities. Am J Cancer Res (2019), 9: 1354-1366 (Year: 2019). [cited by examiner]
Mou et al., Identification of long noncoding RNAs biomarkers in patients with hepatitis B virus-associated hepatocellular carcinoma. Cancer Biomarkers (2018), 23: 95-106 (Year: 2018). [cited by examiner]
Li et al., Exploring functions of long noncoding RNAs across multiple cancers through co-expression network. Scientific Reports (2017), 7: 754, pp. 1-13 (Year: 2017). [cited by examiner]
Jeong et al., Absence of nucleophosmin 1 (NPM1) gene mutations in common solid cancers. APMIS (2007), 115: 341-346 (Year: 2007). [cited by examiner]
Dermani et al., The potential role of nucleophosmin (NPM1) in the development of cancer. J Cell Physiol. (2021), 236: 7832-7852 (Year: 2021). [cited by examiner]
Gourvest et al., A novel leukemic route of mutant NPM1 through nuclear import of the overexpressed long noncoding RNA LONA. Leukemia (2021), 35: 2784-2798 (Year: 2021). [cited by examiner]
Luo et al., Functional characterization of long noncoding RNA Lnc_bc060912 in human lung carcinoma cells. Biochemistry (2015), 54: 2895-2902 (Year: 2015). [cited by examiner]
RP11-196G18.22-001 Transcript and sequence, ENST00000564237, Ensembl Archive released Feb. 2014, https://feb2014.archive.ensembl.org/Homo_sapiens/Transcript/Summary?db=core;g=ENSG00000261716;r=1:149816065-149820591;t=EN… [cited by examiner]
Olivero and Dimitrova, Identification and characterization of functional long noncoding RNAs in cancer. FASEB Journal (2020), 34: 15630-15646 (Year: 2020). [cited by examiner]
Bhatt, Bhumi, et al., “Long non-coding RNA profiling in human skeletalmuscle and their role in Cancer Cachexia.” Journal of Cachexia, Sarcopenia and Muscle. Dec. 2013, vol. 8 issue 6, pp. 1043-1043, XP093067438, doi: 10… [cited by applicant]
Huang, R., et al., “Depletion of the IncRNA RP11-567G11.1 inhibits pancreatic cancer progression.” Biomed Pharmacother. Apr. 2019; 112:108685. doi: 10.1016/j.biopha.2019.108685. Epub Feb. 23, 2019. PMID: 30802827. [cited by applicant]
Ronchetti, D., et al., “A compendium of long non-coding RNAs transcriptional fingerprint in multiple myeloma.” Sci Rep 8, 6557 (2018). https://doi.org/10.1038/s41598-018-24701-8. [cited by applicant]
Wu, W., et al., “Tissue-specific Co-expression of Long Non-coding and Coding RNAs Associated with Breast Cancer.” Sci Rep 6, 32731 (2016). https://doi.org/10.1038/srep32731. [cited by applicant]
Zhang L., et at., “Systematic identification of cancer-related long noncoding RNAs and aberrant alternative splicing of quintuple-negative lung adenocarcinoma through RNA-Seq. Lung Cancer.” Jul. 2017; 109:21-27. doi: 10… [cited by applicant]
Extended European Search Report in European patent application No. 19955708.3 issued Aug. 3, 2023. [cited by applicant]
Office Action issued Jul. 4, 2023 in Japanese patent application No. 2022-535254. [cited by applicant]
Huang R, Nie W, Yao K, Chou J. Depletion of the IncRNA RP11-567G11.1 inhibits pancreatic cancer progression. Biomed Pharmacother. Apr. 2019;112:108685. doi: 10.1016/j.biopha.2019.108685. Epub Feb. 23, 2019. PMID: 308028… [cited by applicant]
Tong W, Yang L, Yu Q, Yao J, He A. A new tumor suppressor IncRNA RP11-190D6.2 inhibits the proliferation, migration, and invasion of epithelial ovarian cancer cells. Onco Targets Ther. Feb. 27, 2017;10:1227-1235. doi: 1… [cited by applicant]
Li, S., Li, B., Zheng, Y. et al. Exploring functions of long noncoding RNAs across multiple cancers through co-expression network. Sci Rep 7, 754 (2017). https://doi.org/10.1038/s41598-017-00856-8. [cited by applicant]
Wang, X., Hu, X., Song, W. et al. Mutual dependency between IncRNA LETN and protein NPM1 in controlling the nucleolar structure and functions sustaining cell proliferation. Cell Res 31, 664-683 (2021). https://doi.org/1… [cited by applicant]
First Office Action issued on Jun. 21, 2021 regarding the corresponding Chinese patent application CN201911265749.8. [cited by applicant]
Written Opinion of International Search Report issued Jun. 14, 2022 regarding WO 2021/114137 A1. [cited by applicant]